Cortexyme Company
Cortexyme is developing treatments for Alzheimer's and other degenerative disorders.
Founded Date:
2012
Total Funding:
225000000
Investor Type:
N/A
Employee Number:
11-50
Investment Stage:
N/A
Funding Status:
IPO
Number Of Exists:
N/A
Technology:
Gene therapy
Last Funding Type:
Post-IPO Equity
Investors Number:
13
Last Funding Date:
2019
Industry:
Biotechnology, Health Care, Medical, Pharmaceutical
Headquarters:
South San Francisco, California, United States
Estimated Revenue:
$10M to $50M